论文部分内容阅读
目的:观察伊立替康联合奥沙利铂治疗广泛期小细胞肺癌(SCLC)的近期疗效和毒副反应。方法:62例广泛期SCLC患者随机分为2组。治疗组32例,伊立替康120mg/m2,静脉滴入,d1、d8;奥沙利铂130mg/m2,静脉滴入,d1;3周为1个周期。对照组30例,依托泊苷80mg/m2,静脉滴入,d1～d5;奥沙利铂130mg/m2,静脉滴入,d1;3周为1个周期。分别评价近期疗效、毒副反应和生存期。结果:治疗组与对照组有效率分别为68.75%(22/32)和46.67%(14/30),χ2=3.10,P=0.08。白细胞减少发生率治疗组(71.88%,23/32)少于对照组(100%,30/30),χ2=7.73,P=0.01。腹泻发生率治疗组(31.25%,10/32)高于对照组(10.00%,3/30),χ2=4.22,P=0.04。而二组1年生存率分别为62.50%和43.33%,χ2=2.28,P=0.13。结论:伊立替康联合奥沙利铂治疗广泛期SCLC相比依托泊苷联合奥沙利铂方案疗效提高,骨髓抑制反应轻,虽然腹泻发生率高,但能够耐受。
Objective: To observe the short-term curative effect and toxicity of irinotecan combined with oxaliplatin in treatment of extensive stage small cell lung cancer (SCLC). Methods: Sixty-two patients with extensive SCLC were randomly divided into two groups. The treatment group 32 cases, irinotecan 120mg / m2, intravenous infusion, d1, d8; oxaliplatin 130mg / m2, intravenous infusion, d1; 3 weeks for a cycle. Control group of 30 patients, etoposide 80mg / m2, intravenous infusion, d1 ~ d5; oxaliplatin 130mg / m2, intravenous infusion, d1; 3 weeks for a cycle. Evaluation of the recent efficacy, toxicity and survival. Results: The effective rates of the treatment group and the control group were 68.75% (22/32) and 46.67% (14/30) respectively, χ2 = 3.10 and P = 0.08. Incidence of leukopenia in the treatment group (71.88%, 23/32) less than the control group (100%, 30/30), χ2 = 7.73, P = 0.01. The incidence of diarrhea in treatment group (31.25%, 10/32) was higher than that in control group (10.00%, 3/30), χ2 = 4.22, P = 0.04. The 1-year survival rates of the two groups were 62.50% and 43.33%, respectively, χ2 = 2.28, P = 0.13. CONCLUSIONS: Irliturian plus oxaliplatin is superior to etoposide plus oxaliplatin in the treatment of extensive-term SCLC. The efficacy of irinotecan in combination with oxaliplatin is mild and its myelosuppression is mild. Although the incidence of diarrhea is high, it can be tolerated.